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1. Introduction 
The identification of additional genetic susceptibility genes in the etiology of AD and the 
metabolic mechanisms leading to differences in age of onset and disease pathogenesis are 
active areas of current susceptibility. Although all the contributing factors may never be 
known, scientists have identified several common threads. They include: age (more than 65 
years old), sex (women are more likely than men are to develop the disease, in part because 
they live longer),  toxicity (such as overexposure to certain trace metals, such as aluminum), 
head injury (serious traumatic injury to the head, for example, a concussion with a 
prolonged loss of consciousness) may be a risk factor for Alzheimer's), hormone 
replacement therapy (the exact role hormone replacement therapy may play in the 
development of dementia isn't yet clear; throughout the 1980s and '90s, evidence seemed to 
show that estrogen supplements given after menopause could reduce the risk of dementia;  
results from the large-scale Women's Health Initiative Memory Study indicated an increased 
risk of dementia for women taking estrogen after age 65: the verdict is not yet in on whether 
estrogen affects the risk of dementia if given at an earlier age), lifestyle (the same factors that 
put you at risk of heart disease, such as high blood pressure and high cholesterol, may also 
increase the likelihood that you'll develop Alzheimer's disease, poorly controlled diabetes is 
another risk factor). Atrial fibrillation, systolic hypertension, and angina have been 
associated with more rapid decline in cognition, while history of coronary artery bypass 
graft surgery, diabetes, and antihypertensive medications were associated with a slower rate 
of decline, and may represent modifiable risk factors for secondary prevention in Alzheimer 
disease. There was an age interaction such that systolic hypertension, angina, and 
myocardial infarction were associated with greater decline with increasing baseline age. The 
attenuated decline for diabetes and coronary artery bypass graft surgery may be due to 
selective survival. Some of these effects appear to vary with age (Mielke et al., 2007). There is 
an overlap of risk factors between VaD and AD, so much so that it raises some serious 
questions about vascular contributions to AD. Recognition that cerebrovascular disease 
causing dementia may be modified by treatment of cerebrovascular risk factors serves as an 
important tool for investigating various treatments aimed at secondary prevention of  
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vascular cognitive impairment (Moretti et al., 2008). Some individuals presenting 
cerebrovascular pathology probably have some component of Alzheimer’s Disease (AD) 
pathology as part of their dementia; this relationship supports the possible interaction 
between cerebrovascular disease, aging and the degenerative process (see data and 
Literature in: Brookmeyer et al., 1998). Various factors may influence the nature and severity 
of brain degeneration. The degree of cerebral grey matter damage, neuronal death, and 
survival will be dictated by the multiplicity, size, and laterality of the tissue injury or the 
extent of vascular disease (Kalaria, 1996; Kalaria, 2010). Anatomical features of the 
circulation, including the size of vessels and vascular wall cellular elements, e.g., arterioles 
versus capillaries, are important factors in defining the pathology. The distribution 
territories of the anterior, posterior, and middle cerebral and the lenticulo-striate arteries 
affect different structures, including the angular gyrus, the caudate nucleus and medial 
thalamus in the dominant hemisphere, the amygdala, and the hippocampus, all structures 
implicated in forms of cognitive impairment (Kalaria, 2010; Ferrer et al, 2008). The origin 
and degree of vascular occlusion or injury and whether this results in ischemic or 
hemorrhagic lesions are further factors that define the extent and severity of damage. 
Alterations in specific genes associated with systemic disease or brain-specific proteins and 
environmental or lifestyle factors may further modify the course of degeneration. On the 
other hand, vascular dementia is defined simply as the syndrome of dementia due to brain 
vascular disease (Hebert et al., 2003).  Numerous epidemiological studies show a high 
prevalence of vascular brain injury amongst the elderly (Wolf et al., 1991; Wu et al., 2002) 
and recent evidence supports a strong association between vascular risk factors and 
dementia (Vermeer et al, 2003; Chui, 1989). Overall in the Western world, vascular disease is 
the second most common cause of dementia (Skoog et al., 1993). However in the very 
elderly, aged 85 years and older, there is a high risk of both stroke and Alzheimer’s disease, 
and the prevalence of VaD is reported to be slightly higher than that of Alzheimer’s disease 
(46.9% and 43.5%, respectively, with some patients possibly having mixed forms of 
dementia) (Skoog et al., 1993). Vascular dementia is a heterogeneous syndrome, grouping 
together a broad category of patients in whom various manifestations of cognitive decline 
are attributed to cerebral- or cardio-vascular disease. The National Institute of Neurological 
Disorders and Stroke and the Association Internationale pour la Recherche et 
l'Enseignement en Neurosciences (NINDS-AIREN) (Roman et al, 1993) elaborated a clinical 
and diagnostic tool, the so- called NINDS-AIREN criterium.  It lists different pathologies, in 
order to identify patients with different subtypes of VaD: multi-infarct dementia (multiple 
large and complete infarcts); post-hemorrhage dementia, and subcortical VaD (small-vessel 
disease). According to NINDS-AIREN, the subcortical VaD (sVaD) is mainly due to lacunar 
infarct, occurring in distribution of small arteriole, usually in the white matter, basal 
ganglia, thalamus and pons, or to microinfarct - not seen on macroscopic examination, small 
area of cystic or non-cystic necrosis surrounded by astrocytes. Incomplete infarct  may also 
be present, due to a selective loss of neurons, myelin, and oligodendrocytes, without cystic 
necrosis, occurring  in the periphery of major artery distribution infarcts (e.g., penumbra) or 
in deep white matter. Incomplete white matter infarcts are associated with myelin pallor, 
astrocytosis, and a variable degree of axonal loss. Subcortical VaD now incorporates the old 
entities ‘lacunar state’ and ‘Binswanger disease’ and relates to small vessel disease and 
hypoperfusion resulting in focal and diffuse ischaemic white matter lesions and incomplete 
ischaemic injury (Erkinjuntti et al 1997; Pantoni et al., 2000).  Assaying cerebrovascular risk 
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factors probably can’t be used for diagnosis of microvascular VaD, but the more risk factors 
there are might have some predictive value. There is an uncanny overlap of risk factors 
between VaD and AD, so much so that it raises some serious questions about vascular 
contributions to AD. Hypertension has often been observed to be a risk factor for VaD 
(Brookmeyer et al., 1998;  Hebert et al., 2000) and sometimes for AD (Posner et al., 2002;  
LAuner et al., 1995;  Morris et al. 2001) although not always (van Dijck et al., 2004). 
Hypertension leads to changes in arterioles and eventually to arteriolar occlusive disease 
and then on to infarction. Hypertension’s effects on the brain in VaD or AD could also be 
related to changes in blood flow or blood-brain-barrier integrity. In fact, a number of 
epidemiological studies show strong associations between elevations in middle-life blood 
pressure and the prevalence of later life cognitive impairment and dementia. Increase in 
systolic blood pressure levels has been associated with more severe periventricular and 
subcortical white matter lesions (van Dijck et al., 2004). People with poorly controlled 
hypertension had a higher risk of severe white matter lesions than those without 
hypertension. But, it clearly merged that a potential negative effect of decreasing diastolic 
blood pressure level on the occurrence of severe periventricular white matter lesions should 
be taken into account. Recent large observational studies have suggested that high blood 
pressure may also play a role in Alzheimer's disease and in the so-called mixed forms of 
dementia, also defined as overlapping syndromes (vascular/degenerative dementia). The 
mechanisms linking hypertension to Alzheimer's disease remain to be elucidated, but white 
matter lesions seen on cerebral magnetic resonance imaging appear to be a good marker of 
this association (Brookmeyer et al., 1998; Ferrer et al., 2008; Tzourio, 2007). Hypertension 
leads to changes in arterioles and eventually to arteriolar occlusive disease and then on to 
infarction, and consequent brain parenchima degeneration (Skoog et al., 1993; 1Hebert et al., 
2000; Posner et al., 2002). A large number of epidemiological studies show strong 
associations between elevations in middle-life blood pressure and the prevalence of later life 
cognitive impairment and dementia. Early evidence suggest that treatment hypertension in 
the elderly may be quite successful in reducing incident dementia. In the Syst-Eur trial 
(Forette et al., 1998), given the high percentage of elderly suffering with untreated 
hypertension, are that secondary prevention treatment trials such as Syst-Eur might have a 
substantial impact on cognitive impairment. Indeed, high blood pressure  may accelerate 
cerebral white matter lesions (Yamamoto et al., 1998; Schmidt et al., 1999), but  white matter 
lesions have been found to be facilitated also by  excessive fall in blood pressure, (Kario et 
al., 1996; Nakamura et al., 1995; Watanabe et al., 1996; Chamorro et al., 1997), including 
orthostatic dysregulation (Matsubayashi et al., 1997) and postprandial hypotension (Kohara 
et al., 1999). The traditional general practice teaches that “the lower the blood pressure is, 
the better is the prognosis”; nevertheless, low blood pressure  as a predictor of increased 
mortality has been described in a 5-year prospective study in Finland (Mattila et al. 1988) as 
well as paradoxical survival of elderly men with high blood pressure (Brookmeyer et al., 
1988; 33Langer et al., 1989). Notwithstanding all of this, interpretations of these so-called J-
shaped curves between blood pressure, and mortality have always been viewed with 
caution and skepticism by epidemiologists and statisticians (Fletcher & Bulpitt, 1992; Glynn 
et al., 1995).  Chronic low blood pressure has been positively associated with a number of 
clinical symptoms and psychosomatic distress—including unexplained fatigue, depression, 
and anxiety—and with minor psychiatric morbidity (de Buyzere et al., 1998). A causal 
relationship between low blood pressure and low mood remains uncertain, but a vicious 
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circle should not be excluded (de Buyzere et al., 1998). Zhu et al. (1998) observed that there 
was a correlation between  systolic pressure reduction and cognitive decline in women, 
which was not accounted for by other factors.  Baseline blood pressure level was not 
significantly related to cognitive decline in that sample with initial good cognition. The 
Authors speculated that blood pressure reduction might be an early change of the 
dementing process (see also literature in Gorelick, 1997), even if no clear statement merges 
on this point (Ferrer et al., 2008). Ruitenberg et al. (2001) found out that lower  systolic and 
diastolic blood pressures at baseline were associated  with a higher risk of dementia at 
follow-up. This association was observed across all age strata, in men as well in woman and 
both in Alzheimer’s disease and vascular dementia. Subjects with incident dementia also 
decreased more in blood pressure level than in persons without dementia, even if not 
significantly (Ruitenberg et al., 2001). This may reflect that low blood pressure causes or 
contributes to dementia or that incipient dementia leads a drop in blood pressure 
(Ruitenberg et al., 2001). The authors suggested that for the first part of the proposition, they 
observed an inverse association between blood pressure and dementia mainly in subjects, who 
used antihypertensive medication (Ruitenberg et al., 2001). This may indicate that their 
hypertension was longer lasting, and perhaps that these patients were more susceptible to 
pressure drops, causing inadequate cerebral blood flow. That would be particularly important 
in vulnerable areas, such as watershed zones and white matter. A second explanation given by 
the authors (Ruitenberg et al., 2001) was that low pressure  might be a consequence of an 
incipient dementia. The Authors found that blood pressure was lower in subjects with 
manifest dementia, and those with dementia, who presented lower pressure, declined more 
rapidly. The possible explanation given by these Authors (Ruitenberg et al., 2001) is that 
several areas are involved in pressure regulation; Burke et al. (1994) reported a strong 
correlation between the decrease of the number of C1 neurones in the medulla oblongata and 
blood pressure dysregulation in Alzheimer patients.  Guo et al. (1999) examined whether 
initially low blood pressure is related to the incidence  of dementia and showed that 
individuals with baseline systolic pressure  of 140 mmHg or less had a significantly higher risk 
of dementia and Alzheimer’s disease.  That was the first study that has reported clearly an 
association between relatively low systolic pressure and increased incidence of dementia with 
a  particular presumable sufferance of brain parenchima, generally hypoperfused in dementia 
patients (Brown & Frackowiak, 1991), related to an impairment of the cerebral autoregulation, 
secondary to the degenerative disorder. The direct consequence would be a sequential ulterior 
reduction of blood pressure, due to dysregulation, which might accelerate the lowering of 
blood perfusion, altered regulation flow capacity,  and therefore the underlying degenerative 
process (Forette et al., 1998 Bolster et al., 2001; Nilsson et al., 2007).  Starting from these studies, 
we would like to prove if hypotension is a key point in vascular dementia patients, and  if this 
aspect reflects its importance in the daily living assistance. 
2. Subjects and methods 
2.1 Patients 
Study subjects were men and women aged 68–94  years, entering in Cognitive Disorder Unit 
Evaluation of the University of Trieste,  with Mini-Mental State Examination (MMSE) scores 
of at least 14 (Folstein et al., 1975) and satisfying the fourth edition of the Diagnostic and 
Statistical Manual of Mental Disorders (APA, 2000) for dementia, recruited from June 1st 
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2007 to December 31st 2010. We have examined 2657 patients, who have been diagnosed as 
suffering from Mild Cognitive Impairment, Alzheimer’s Disease, Frontal Lobe Dementia, 
Lewy Body Dementia  and Parkinson – dementia complex. 1047 patients suffered from 
vascular dementia: 183 have been diagnosed as Multi-Infarct Dementia. 864 patients 
suffered from subcortical vascular dementia: these study subjects satisfied the criteria for 
probable VaD in accordance with the NINDS-AIREN criteria (Roman et al., 1993). A patient 
was diagnosed as having subcortical VaD (sVaD) when the CT/MRI scan showed moderate 
to severe ischemic white matter changes (Erkinjunnti et al., 2000) and at least one lacunar 
infarct.  Brain CT-scans or MRI images were randomized and assessed independently, after 
the radiologist’s opinion,  by neurologists (RM, PT). Patients were not included in the study 
if they showed signs of normal pressure hydrocephalus, previous brain tumors, previous 
diagnosis of major stroke or brain hemorrhage. We did not include patients with white 
matter lesions, caused by specific etiologies, such as multiple sclerosis, brain irradiation, 
collagen vascular disease, and genetic forms of vascular dementia (such as CADASIL or 
CARASIL). Patients with previous major psychiatric illness (i.e. schizophrenia, bipolar 
disorders, psychosis, compulsive-obsessive disorders, etc) or central nervous system 
disorders and alcoholism were excluded too.  
2.2 Study design 
This was a prospective cohort study, designed to investigate gait (balance and equilibrium) 
disorders, behavioral alterations, drug intake of a subcortical dementia population. Study 
subjects were 646 men and women, diagnosed as previously stated as subcortical vascular 
dementia (sVaD), not bedridden, aged 68-94 years outpatients, recruited from  June, 1st 2007 
to December, 31st 2010,   who underwent a standardized baseline assessment that included 
a detailed history, a physical examination, laboratory tests and psychiatric evaluations. The 
physical examination included evaluations of pulse rate and rhythm, blood pressure, heart 
size and sounds, peripheral pulses, retinal vessel and carotid artery evaluation, 
electrocardiographic evaluation, and chest X-ray.  The physical examination was repeated at 
every visit; electrocardiographic evaluation and laboratory tests were repeated every 3 
months. Caregivers have been instructed to measure blood pressure 3 times/week, baseline 
and after two minutes in hortostatism and write the evaluation in a diary, which we checked 
at each visit.  Patients in both groups were allowed to continue any previous therapy (e.g. 
cholinesterase inhibitors, antihypertensive, antidyslipidemic, antidiabetic drugs). (Table 1). 
Patients were divided in two groups: those with hypertension history and at baseline, who 
progressively registered low blood pressure (415 patients) and  those with hypertension 
history, who maintained elevated values of systolic/diastolic pressure (398 patients). From 
this point, the former will be defined as group A, the latter as group B. All patients were 
followed with periodical neurological and neuropsychological examinations. Visits were 
scheduled to take place every four months. A complete neuropsychological examination 
was conducted at baseline, and every 6 months; every 12 months’ results were compared.  
The trial was conducted in accordance with the Declaration of Helsinki and with the Ethics 
Guidelines of the Institute.  
2.3 Outcome measures 
Global performance was assessed using the Ten Point Clock test  (Manos, 1997)  at every 
visit. Behavioral symptoms were assessed using the Neuropsychiatric Inventory (NPI) 
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(Cummings et al., 1994) at every visit. In particular, we have examined   sub-item “apathy”, 
from the complex of NPI evaluation system. The Complex activities of daily living were 
evaluated by the Instrumental activity of Daily living (IADL) (Lawton & Brody, 1969). 
Frontal Battery has been evaluated every three months (Dubois et al., 1997). Mobility 
problems were assessed by the Tinetti scale for equilibrium/balance and gait (Tinetti, 1986) 
at every visit. Hachinski Ischemic score (HIS) was  done (Hachinski et al., 1973). Patients 
were registered for their medical intake and for their blood pressure diaries. 
2.4 Statistical analyses 
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS, version 16.0). Within- and between -group changes from baseline to 12, 24 and 36 
months were tested using the Wilcoxon Signed Ranks test. This was done for the overall 
scores for each efficacy variable.  Spearman's   rank   correlation analyses were performed 
between behavioral outcome measures (NPI), Tinetti scale, Ten Point Clock Test (TPCT), 
FAB assessment score, Apathy, and  BI. Results are presented as mean changes from 
baseline with standard deviations, and P-values are presented where appropriate. 
3. Results 
We have examined 2657 patients, who have been diagnosed as suffering from Mild 
Cognitive Impairment, Alzheimer’s Disease, Frontal Lobe Dementia, Lewy Body Dementia  
and Parkinson – dementia complex. 1047 patients suffered from vascular dementia: 183 have 
been diagnosed as Multi-Infarct Dementia. 864 patients suffered from subcortical vascular 
dementia. These patients,  415 men and 449 women, were included in the study (Table 1).  
 
Age in years (mean ± SD) 72.4 ± 5.8 
Gender (male/female) 401/412 
Education level in years (mean ± SD) 10.4 ± 2.3 
Concomitant illnesses (N.+ % patients) 
Essential hypertension 794 (97.6%) 
Diabetes mellitus, type 2 236 (29.1%) 
Ischaemic cardiopathy/valvular failure/arrythmias 413 (50.8%) 
Chronic obstructive bronchopathy 205 (25.2%) 
Neoplasia 36 (4.4%) 
Table 1. Baseline characteristics of patients. 
Their mean age was 72.4 + 5.8 years, and they had a mean education level of 10.4 + 2.3 years.  
The diagnosis was based on historical  information and neuropsychological assessment and 
supported by findings on structural (CT or magnetic resonance)  imaging. Subsequent 
follow-up of subjects has reinforced the clinical diagnoses in all cases. Brain CT-scans or 
MRI images were available for all the 864 selected patients; all the patients attended CT 
scans,  246 patients did, moreover,  MRI studies.  These  246 patients were requested by us 
to complete their diagnostic route with MRI sequences, in case of not adequate imaging 
acquisition, or not convincing data. Thirty one  patients died during follow-up; twenty 
patients did not have a caregiver, who could guarantee adequate compliance, and therefore 
have been excluded, after the first year from the study. All the other 813 patients  (401 men 
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and 412 women) completed the full 36-month study. Patients were allowed to continue any 
previous therapy (e.g. antihypertensive, antidyslipidemic, antidiabetic drugs) (Table 2).  
 
Drug utilization mg/day baseline 
12 
months 
24 
months 
36 months 
ACE inhibitor 
412 
patients 
292 
patients 
203 
patients 
173 patients 
Sartan 
283 
patients 
169 
patients 
179 
patients 
143 patients 
Calcium antagonists 
345 
patients 
172 
patients 
167 
patients 
158 patients 
Two or more (Antihypertensive) 
drugs together 
246 
patients 
0 0 0 
Antidiabetic medication 
186 
patients 
251 
patients 
198 
patients 
105  patients 
Antiplatetelet drugs 
321 
patients 
349 
patients 
430 
patients 
349 patients 
ASA 
247 
patients 
344 
patients 
376 
patients 
389 patients 
Digoxin 
223 
patients 
215 
patients 
175 
patients 
125 patients 
Diuretics 
153 
patients 
187 
patients 
178 
patients 
196 patients 
Thiazide diuretics 
165 
patients 
143 
patients 
189 
patients 
110 patients 
Lipid lowering drugs 
 
156 
patients 
189 
patients 
265 
patients 
311 patients 
Nitroglycerine or analogue 
234 
patients 
254 
patients 
209 
patients 
148 patients 
Bronchodilators 
 
121 
patients 
87 
patients 
97 
patients 
104 patients 
A combination of the above 
therapies 
512 
patients 
683 
patients 
545 
patients 
631patients 
Table 2. A synopsis of the drugs employed by the two groups of patients at baseline 
During the follow-up, the patients were prescribed neuroleptics and/or benzodiazepines 
(Table 3).  
 
Drug utilization baseline 12 months 24 months 36 months 
Benzodiazepines 144 patients 289 patients 276 patients 314 patients 
Typical neurolpetics 78 patients 356 patients 498 patients 577 patients 
Atypical  neurolpetics 24 patients 115 patients 167 patients 345 patients 
Two or more drugs 203 patients 345 patients 406 patients  567 patients 
Table 3. A synopsis of the SNC drugs employed by the patients 
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The patients were homogeneously recruited and no demographical/social/ cultural/clinical 
difference distinguish from each other. Patients were divided in two groups: those with 
hypertension history and at baseline, who progressively registered low blood pressure (415 
patients), and those with hypertension history, who maintained elevated values of 
systolic/diastolic pressure (398 patients). From this point, the former will be defined as 
group A, the latter as group B. Two neurologists of the group revised all the imaging, 
employing the Blennow et al. (1991) scale for CT scans and the Scheltens et al. (1993) scale 
for MRI imaging. There was 94.2% inter-rater agreement for the independent assessment of 
the scans (kappa=0.76). Considering the global health conditions, there was an obvious 
deterioration in the patients as evidenced by the increase of the daily drug uptake (Table 3). 
Main scores obtained by the patients, during the follow-up have been reported in table 4 as 
mean and SD . Particularly, the results obtained in the FAB scale,  Tinetti Scale, apathy (as 
sub-score of NPI) have been reported in table 4a which reports the differences within Group 
A, in the follow-up; in table b, it has been reported the differences within Group B during 
follow-up; in table 4c it has been reported the differences between the two groups in the 
follow-up. According to a Wilcoxon Signed Ranks test, there was a general worsening of the 
cognitive, behavioral and instrumental capacities of the patients observed in the 36 months 
of follow-up within the two groups (table 4a and 4b). It has been showed that there was an 
evident difference between groups, as evidenced in table 4c: no significant difference has 
been registered between the two groups at baseline, a part from the performance obtained at 
the FAB test (p<0.05). At twelve, twenty four and thirty six months, the differences between 
the two groups were significant (p<0.01) as demonstrated by table 4c.  
 
Tests Baseline 12 months 24 months 36 months 
 
Group 
A 
Group 
B 
Group 
A 
Group 
B 
Group 
A 
Group 
B 
Group 
A 
Group 
B 
TPCT 
7.7 ± 
0.2 
7.4 ± 
0.5 
6.1 ± 
0.1 
6.8 ± 
0.3 
5.4 ± 
0.2 
6.1 ± 
0.5 
4.1 ± 
0.1 
5.9 ± 
0.6 
NPI 
24.5 ± 
3.2 
23.5 ± 
2.4 
41.4 ± 
2.1 
34.5 ± 
3.2 
66.4 ± 
1.1 
64.5 ± 
2.7 
86.3 ± 
9.1 
74.5 ± 
3.2 
Apathy 
(NPI) 
6.6± 
0.2 
6.2 ± 
0.4 
8.3 ± 
0.1 
6.8 ± 
0.6 
9.2 ± 
0.5 
7.9 ± 
0.7 
11.1± 
0.2 
9.6± 
0.1 
FAB 
13.3 ± 
1.2 
14.1 ± 
1.1 
10.3 ± 
0.5 
11.1 ± 
1.1 
9.3 ± 
0.9 
10.8 ± 
1.3 
8.4 ± 
0.2 
10.1 ± 
0.9 
Barthel 
Index 
89.1 ± 
5.3 
87.1 ± 
6.2 
81.1 ± 
1.2 
83.1 ± 
2.4 
76.8 ± 
6.1 
81.1 ± 
4.1 
61.1 ± 
7.3 
69.1 ± 
4.3 
Tinetti 
score 
21.8 ± 
1.8 
22.1 ± 
1.1 
18.3 ± 
1.4 
21.4 ± 
1.4 
17.7 ± 
1.5 
21.1 ± 
0.5 
15.7 ± 
1.6 
19.1± 
1.1 
Hachinski 
Ischemic 
Score 
7.6 ± 
0.1  
8.1 ± 
0.3 
6.4 ± 
0.11 
7.9 ± 
0.1 
6.2 ± 
0.3 
7.3 ± 
0.1 
6.2  ± 
0.1 
6.9 ± 
0.3 
Table 4. Tests results in the patients observed during follow-up 
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Tests 
12 months vs 
baseline 
24 months vs 
baseline 
36 months vs 
baseline 
TPCT 0.9 ± 0.3 p<0.01 5.4 ± 0.1  p<0.01 3.6 ± 0.2  p<0.01 
NPI -16.9 ± 1.3 p<0.01 -41.9 ± 4.3 p<0.01 -61.8 ± 2.1  p<0.01 
Apathy (NPI) -1.7 ± 0.4 p<0.01 -2.6 ± 0.3 p<0.01 -4.5 ± 0.1  p<0.01 
FAB 3.2 ± 0.7 p<0.01 4.3 ± 0.3 p<0.01 4.9 ±1.0  p<0.01 
Barthel Index 8± 9.3 p<0.01 12.3 ± 5.1 p<0.01 28 ± 4  p<0.01 
Tinetti score 3.5 ± 0.4 p<0.01 4.1 ± 1.3 p<0.01 6.1 ± 0.2  p<0.01 
Hachinski Ischemic 
Score 
0.8 ± 0.3 p<0.01 1.4 ± 0.2 p<0.01 1.4 ± 0.1  p<0.01 
Table 4 a. Tests results in the patients observed during follow-up in Group A 
 
Tests 
12 months vs 
baseline 
24 months vs 
baseline 
36 months vs 
baseline 
TPCT 0.6 ± 0.1  p<0.05 1.3 ± 0.1  p<0.05 1.5 ± 0.2  p<0.01 
NPI -11 ± 1.2  p<0.05 -41 ± 0.3  p<0.05 -51 ± 2.1  p<0.01 
Apathy (NPI) -0.6 ± 0.2  p<0.05 -1.3 ± 0.2 p<0.05 -3.4 ± 0.3  p<0.01 
FAB 3 ± 0.1  p<0.05 3.3 ± 0.2  p<0.05 4 ±0.2  p<0.01 
Barthel Index 4 ± 2.8  p<0.05 6 ± 2.1  p<0.05 26 ± 1.5  p<0.01 
Tinetti score 0.7 ± 0.2  p<0.05 1.1 ± 0.6  p<0.05 6.4 ± 1.4  p<0.01 
Hachinski Ischemic 
Score 
0.2 ± 0.2  p<0.05 1 ± 0.2  p<0.05 1.2 ± 0.3  p<0.01 
Table 4 b. Tests results in the patients observed during follow-up in Group B 
 
Tests baseline 
12 months vs 
baseline 
24 months vs 
baseline 
36 months vs 
baseline 
TPCT -0.3 ±0.2 ns -0.8 ±0.2 p<0.05 0.6 ±0.3 p <0.01 1.8 ±0.5 p<0.01 
NPI -1 ±0.8 ns 6.9 ±1.1 p <0.05 1.9 ±1.6 p <0.01 
-11.38 ±5.9 p 
<0.01 
Apathy (NPI) -0.4 ±0.2 ns 1.5 ±0.5 p <0.01 2.7 ±0.2 p <0.01 
-1.5 ±0.1 p 
<0.01 
FAB -0.8 ±0.2 p<0.05 
-1.2 ±0.6 p 
<0.05 
-1.5 ±0.4 p 
<0.01 
1.7 ±0.5 p <0.01 
Barthel Index -2 ±1.7 ns 
-2.1 ±1.2 p 
<0.05 
-4.3 ± 2 p <0.01 8.0 ±3.0 p <0.01 
Tinetti score -0.3 ±0.7 ns 
-3.1 ±0.1 p 
<0.05 
3.4 ± 1 p <0.01 4.6 ±0.5 p <0.01 
Hachinski 
Ischemic Score 
-0.5 ±0.2 ns 
-1.5 ±0.1 p 
<0.05 
-1.1 ±0.2 p 
<0.01 
0.37 ±0.2 p 
<0.01 
Table 4 c. Tests results in the patients observed during follow-up B vs A 
In group A, blood pressure mean values are 130/80 ± 6.5 mm Hg at baseline, and then a 
decrease of 10.4 ± 7.5 mm Hg at twelve months, 15.6  ± 6.7 mm Hg at twenty four months, and 
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18.7   ± 5.3 mm Hg at thirty six months. In group B, blood pressure mean values are 150/85 ± 
10.2 mm Hg at baseline, and then a decrease of 8.4 ± 3.5 mm Hg at twelve months, 7.6  ± 3.5 
mm Hg at twenty four months, and 11. 2  ± 5.3 mm Hg at thirty six months. In group A, there 
was a dramatic decrease of anti-hypertensive drugs prescriptions. In group B, patients 
maintained their original prescriptions, though under strict medical follow-up. Spearman’s 
rank correlation analyses indicated that there was a significant correlation between NPI scores 
and Tinetti score over 24 months (NPI= 56.84 ±12.11, r=0.81, p<0.01), over 36 months  (NPI= 
66.03 ±8.81, r=0.87, p<0.01), in both group. Though it has been evidenced a significant decrease 
of Tinetti score in Group A, with low blood pressure than in Group B (see table 4, 4 1, b and c). 
We have found a correlation between benzodiazepines  and neuroleptics intake and Tinetti 
score at 12, 24 and 36 months (respectively r=0.77, p<0.05; r=0.78, p<0.05; r=0.67, p<0.05  at 12 
months; r=0.81, p<0.01; r=0.77, p<0.05; r=0.84, p<0.01  at 24 months; r=0.81, p<0.01; r=0.82, 
p<0.01; r=0.89, p<0.01  at 36 months) in both Groups.  We have observed a positive correlation 
between apathy and NPI total scores in both the groups over 12, 24 and 36 months 
(respectively r=0.78, p<0.05; r=0.8, p<0.05 at baseline; r=0.82, p<0.01;   r=0.67, p<0.05;   at 12 
months; r=0.86, p<0.01; r=0.77, p<0.05 at 24 months; r=0.91, p<0.01; r=0.82, p<0.01 at 36 
months). Finally, we did observe a positive correlation between apathy scores and FAB scores 
only in Group A at every session; in Group B at 24 and at 36 months (respectively r=0.78, 
p<0.05 at baseline; r=0.82, p<0.01 at 12 months, only for Group A; r=0.86, p<0.01; r=0.77, 
p<0.05 at 24 months; r=0.91, p<0.01; r=0.82, p<0.01 at 36 months, respectively). 
4. Discussion 
We have studied well selected 864 patients, for three years, suffering from subcortical 
vascular dementia. Our aim has been to prove if hypotension is a key point in vascular 
dementia patients, and  if this aspect reflects its importance in the daily living assistance. 
What we have observed are different points. Subcortical vascular dementia is related 
somehow to hypertension, mainly because ) all the  patients recruited have been 
diagnosed hypertension, during their life. Curiously, some of them (n=415; group A), 
during the follow-up, registered a dramatic decrease of their blood pressure values, 
constantly during the entire follow-up, even if the anti-hypertensive drugs have been 
interrupted; some other (n=398; group B), who had a hypertension history, but 
maintained elevated values of systolic/diastolic pressure during the entire follow-up. 
These patients have been studied, and what merged is that the two groups did not differ 
from a neurological, behavioral, and general drug intake at baseline; there was only a 
significant difference in cognition performance, as far as group A frontal functions 
(implementation of strategies, executive function, judgment  capability, abstract 
reasoning, go/no go strategies and auto-inhibition) appear significantly worse (p<0.05) 
than those of Group B. During follow-up, both patients did worse, in their life functions, 
as far as cognition, behavior, gait, functional independence; but, during the entire follow-
up, Group A did worse in all the items when compared to Group B. In particular, these 
patients were referred as more apathic, abulic, with less frontal performances, with major 
walking impairment and with lower independence. In other words, it seems that given a 
selected population, in which hypertension has been correctly established and treated, it 
might have led to a well-defined  white-matter  deterioration (the previously called 
Binswanger’ disease); then, when dementia has been diagnosed, the sudden modification 
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of blood pressure regulation, changed in hypotension, led to a poorer life expectance, due 
to a worse performance in cognition (as above mentioned), behavior (more apathy and 
abulia), walking strategies. All these aspects reflect a functional sufference of frontal 
subcortical neural pathways: it is not known the reason, but frontal lobes have a 
metabolism rate under basal condition that is 20% more than that of the other brain areas 
(Moretti, 2006). And it is also well known that age cognitive modifications are related to 
frontal dysfunctions (Levine et al., 1997; Esposito, 1999; Kramer et al., 1999), due to a 
reduction of brain reserve capacity. This brings an aged individual closer to the level of 
insufficiency where only minor additional lesions may be required to precipitate 
dementia. The degenerative aging changes, though milder, repeat much of the pathology 
of Alzheimer's disease.  In vascular dementia, especially in subcortical vascular type, 
there is an accentuate expression of what is found in old age (Moretti, 2006). The complete 
and incomplete white matter infarction, frequently coexisting, would, by virtue of their 
high prevalence, be the underlying substrate in the recognition of white matter disease 
(Capizzano Aristides et al., 2007), leuko-encephalopathy or leuko-araiosis (Hachinski, 
1994). Having this point stated, it should be consider another question: why are these 
patients so sensitive to hypotension? And another major problem is: why do these 
patients change their historical profile and suddenly have low blood pressure, having a 
positive history of hypertension and not clear signs of new concomitant pathologies, 
which can determine, per se, low blood pressure? The hypothesis here are suggestive, but 
not at all conclusive. The small artery vessels of an hypertensive patient show a 
degeneration of the smooth muscle layer, which is replaced by collagen in a hyaline 
fibrosis, leading to a subtotal luminal occlusion. These arterioles share traits with non-
hypertensive lipohyalinosis (Zhang et al, 1994), as well as with hypertensive 
arteriolosclerosis,  and may concur with hypertensive changes. Anatomically, the smaller 
resistance blood vessels undergo degenerative changes consisting of thickening and 
fibrosis of the media (in muscular arteries) and intima, and patchy degeneration of 
smooth muscle cells producing luminal narrowing and increased vascular resistance. 
Although the resting CBF is the same in normotensive and hypertensive individuals, 
these structural changes limit the capacity of the resistance vessels for maximal 
vasodilatation and impair tolerance of lower blood pressures, while improving tolerance 
to hypertension through vasoconstriction of these same vessels. Long-term 
antihypertensive treatment can reverse these adaptive changes and shift the auto-
regulation curve back to its normal range, although only limited reversibility occurs in 
elderly hypertensive patients (Moretti et al., 2008).  Moreover, it has been observed that 
there is another possible explanation which might be related to the sudden dys-regulation 
observed in these patients.  Relatively low blood pressure seems to be correlated with 
dementia even in a preclinical stage.  Different Authors (Guo et al., 1991) started  from the 
speculation that cerebral blood flow is reduced in dementia patients (Brown & 
Frackowiak, 1991). That was generally thought to be related with reduced metabolic 
activity of the brain or with a major vascular lesion. The authors hypothesized that the 
reduction of cerebral blood flow might be related to the impairment of the cerebral 
autoregulation, secondary to the degenerative disorder. The direct consequence would be 
a sequential ulterior reduction of blood pressure, due to dys-regulation, which might 
accelerate the lowering of blood perfusion and therefore the underlying degenerative 
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process (Yamamoto et al., 1998; Bolster et al., 2001; Nilsson et al., 2007; Mehagnoul-
Schipper et al., 2002). Moreover, the authors interpreted these results as a potential 
expression of the frailty and deteriorated vitality of the oldest old, in keeping constantly 
the auto-regulation capabilities of the normal brain, and expressed their concern, due to 
this frailty, on the real impact of lowering pressure in oldest age (Nilsson et al., 2007).  An 
age-related impairment of the vascular auto-regulation  due to impaired functioning of 
the autonomic nervous system can lead to symptoms derived from blood pressure altered 
dysregulation in the elderly. Additionally, age-related arteriolar changes, including 
endothelial changes, have been suggested to reduce the baroreflex activity and thereby 
predispose for deleterious blood pressure falls (Salloway, 2003). The prevalence of 
orthostatic and non-orthostatic hypotension reached 50% in clinically evaluated VaD 
cases (Salloway et al., 2003; Mirski, 2005).  The possible liaison  that relates lower blood 
pressure, dysregulation of cerebral blood flow, vascular dementia,  (and eventual AD 
dementia) might be the pivotal role of acetylcholine (Ach). Ach regulates the cerebral 
blood flow through the parasympathetic innervation of the circle of Willis and of the pial 
vessels (Vasquez & Purve, 1979), and it causes significant arterial relaxation by promoting 
the synthesis of vasodilator agents (Vanhoutte, 1989).  Preclinical research using the 
spontaneously hypertensive stroke-prone rat model of VaD has shown a significant 
reduction in the levels of acetylcholine (ACh) and choline in the cortex, hippocampus and 
cerebrospinal fluid compared with normal rats (Kimura et al., 2000). When compared 
with normal rats, spontaneously hypertensive stroke-prone rats have significantly lower 
levels of acetylcholine in the cerebrospinal fluid (CSF) (Togashi et al., 1994).  In the latter 
study, the differences in CSF levels between normal rats and stroke prone rats increased 
with age, suggesting progressive deterioration of central cholinergic function in  
hypertensive stroke prone rats. The cholinesterase inhibitor epistigmine has been shown 
to improve blood flow in the Sprague-Dawley rat with tandem occlusion of left middle 
cerebral and common carotid arteries. Epistigmine also enhanced the ischaemia-induced 
rostral shift of cerebral blood flow maximum in the contralateral hemisphere and the 
redistribution of cerebral blood flow, a phenomenon possibly related to recovery of 
function (Scremin et al., 1997). Very recently, to prove the role of acetylcholine in vessel 
regulation muscarinic receptors, M5, have been studied. The M5 muscarinic receptor is 
the most recent member of the muscarinic acetylcholine receptor family (M1-M5) to be 
cloned. Because M5 receptor mRNA has been detected in several blood vessels, Yamada et 
al. (2001) investigated whether the lack of M5 receptors led to changes in vascular tone by 
using several in vivo and in vitro vascular preparations in knockout mice. Strikingly, 
acetylcholine, a powerful dilator of most vascular beds, virtually lost the ability to dilate 
cerebral arteries and arterioles in M5R_/_ mice. This effect was specific for cerebral blood 
vessels, because acetylcholine-mediated dilation of extra-cerebral arteries remained fully 
intact in M5R_/_ mice.  Therefore, as often happens in neurological studies, the more 
hypotheses, the more questions: why should patients with the same pathology (subcortical 
vascular dementia) respond so differently to blood pressure regulation? What is the role of 
blood pressure dysregulation in sVAD patients, without a previous history of hypertension? 
Should we consider the possibility to treat differently patients with dementia and 
hypertension? More studies should consider these fundamental points, in order to 
implement knowledge and eventfully ameliorate treatment options for vascular dementia. 
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5. Conclusions 
In conclusion, we could state: 
1.  low flow states are critical to the pathogenesis of ischemic leuko-encephalopathy; in 
particular this is particularly true in subcortical vascular dementia, where the cerebral 
frontal subcortical regions are particularly sensitive to hypo-perfusion 
2. We do not know several points: is hypotension a primary event in vascular dementia or 
is it secondary to the degeneration of brain structure? What is the role of acetylcholine 
in blood flow dys-regulation? Why do patients with dementia have such different 
response to blood pressure control? 
3. Taking into considerations all these points, we strictly recommend to the clinicians who 
face every day these patients that they should check strictly blood pressure, and that 
they should taper anti-hypertensive medications according to aging-associated declines 
in BP and tendency toward orthostasis? The neurological concept of “tailored therapy” 
should begin with the most huge and wide-spread diffused drugs, such as hypertensive 
drugs 
4. In frail patients, such as the old patients with dementia, clinicians should consider the 
concept of the minimization of ancillary drugs, e.g. anti-diabetes, bronchodilators, 
diuretics, anty-arythmics, and so on. The entire drug set should be reconsidered at 
every visit, taking into account the real state of the patients, updated at the moment 
5. Benzodiazepines and other meds that could lower BP in the elderly should be 
prescribed when necessary, without doubts, but the prescriptions should be followed 
during the time course of the life span of the demented patients. 
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